Otsuka buys Astex for $866 million
September 6, 2013Sales and Marketing Astex, Lundbeck, Onyx, Otsuka
Otsuka Pharmaceutical is to buy UK-based Astex Pharmaceuticals in a deal that will see the Tokyo-based firm shelling out $866 …
NSF appoints senior director
September 6, 2013Manufacturing and Production, Research and Development, Sales and Marketing NSF, Toscano
Public health organisation NSF International has appointed George Toscano as senior director of Quality Systems, Pharmaceuticals, Biotech and Biologics. Toscano …
More cash for ‘paperless NHS’
September 5, 2013Medical Communications, Sales and Marketing DoH, Hunt, NHS, paper free
The government has announced £1 billion funding for IT projects to help deliver its commitment to a paperless NHS by …
NICE queries pharma R&D costs
September 5, 2013Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D
NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …
GSK cancer vaccine fails in Phase III
September 5, 2013Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III
GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …
New leadership roles at Novella Clinical
September 5, 2013Manufacturing and Production, Research and Development, Sales and Marketing CRO, novella clinical
Contract research organisation Novella Clinical has announced that three senior executives have assumed new leadership roles within the firm. Deborah …
AstraZeneca begins olaparib programme
September 4, 2013Sales and Marketing AstraZeneca, olaparib, ovarian cancer
AstraZeneca has begun recruitment in its Phase III programme for olaparib, a potential first-in-class oral poly ADP ribose polymerase (PARP) …
Transparent implant opens ‘window’ on the brain
September 4, 2013Medical Communications, Research and Development, Sales and Marketing UC, YSZ, brain
Researchers have developed a cranial implant that could act as a brain ‘window’, making life-changing procedures safer and easier. The …
GSK faces new China allegations
September 4, 2013Medical Communications, Sales and Marketing China, GSK, bribery
GlaxoSmithKline is facing a potential worsening of its already embarrassing situation in China, where the UK-based group has been accused …
RSA hires Chris Molloy as chief executive
September 4, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Molley, rsa
Life sciences executive search and interim management firm RSA has announced the appointment of Chris Molloy as its chief executive. …
Amgen/Cytokinetics heart drug fails in clinical trial
September 3, 2013Research and Development, Sales and Marketing Amgen, Novartis, cytokinetics, omecamtiv mecarbil
A new heart failure drug by Amgen and Cytokinetics has fallen short of its primary endpoint in a Phase II …
GSK’s skin cancer pill Tafinlar gets EMA approval
September 3, 2013Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma
GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …
Aubagio approved in Europe
September 3, 2013Sales and Marketing Aubagio, Genzyme, Rebif, Sanofi, tecfidera
Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …
Rare disease drugs ‘need separate budget’
September 3, 2013Research and Development, Sales and Marketing NHS, NICE, rare diseases
A group of MPs in the UK are calling for a ring-fenced fund to pay for drugs for rare and …
CordenPharma gets bigger in peptides
September 3, 2013Manufacturing and Production API, CordenPharma, Solvay, peptides
Solvay has reached an agreement to sell its peptide subsidiary Peptisyntha SA to the holding company behind contract manufacturing organisation …
Women in the pharma industry
September 3, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson and Johnson, adams, women
In the past pharma has been accused of being too male-orientated in both the laboratory and the boardroom. The idea …
EU green light for ‘new’ Herceptin
September 3, 2013Sales and Marketing EU, Herceptin, Roche, breast cancer
Roche has ticked another approval off Herceptin’s list with the news that the European Commission is allowing a new form …
Proveca appoints former ABPI and AZ president
September 3, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AZ, Brinsmead, Proveca
The former president of AstraZeneca and the ABPI has been appointed as chairman of pharma firm Proveca. Chris Brinsmead joins …
Edoxaban ‘as effective as warfarin’
September 2, 2013Sales and Marketing DVT, Daiichi Sankyo, VTE, warfarin
Daiichi Sankyo is celebrating after its once-a-day blood thinner edoxaban proved as effective as warfarin in a late-stage trial, although …
Health app data ‘shared’
September 2, 2013Medical Communications, Sales and Marketing health apps, pharma
It has been reported that user information from some of the most popular health and wellbeing apps is being transmitted …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
